Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer

靶向免疫抑制肿瘤微环境，提高口腔癌放疗和免疫放疗的疗效

• 批准号: 10595710
• 负责人: Ananth V Annapragada
• 金额: $ 2.1万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10595710
• 关键词: Acute; Adoptive Transfer; Antitumor Response; Automobile Driving; Binding; Body part; CD8-Positive T-Lymphocytes; Cancer Etiology; Cancer Model; Cell physiology; Cells; Chronic; Clinical; Clinical Research; Clinical Trials; Clinical effectiveness; Combined Modality Therapy; Cyclophosphamide; Data; Deglutition; Dose; Drug Delivery Systems; Drug Formulations; Effectiveness; Effector Cell; Equilibrium; Goals; Head and Neck Cancer; Human Papillomavirus; Immune; Immune checkpoint inhibitor; Immune response; Immune system; Immunologics; Immunomodulators; Immunosuppression; Immunotherapeutic agent; Immunotherapy; Impairment; Integrin alpha4beta1; Ligands; Mediating; Memory; Microscopic; Modeling; Mucositis; Mus; Myeloid-derived suppressor cells; NOS2A gene; Nitric Oxide Synthetase Inhibitor; Oral Characters; Oral cavity; Oropharyngeal; PD-1/PD-L1; Patient Education; Pharyngeal structure; Postoperative Period; Radiation; Radiation therapy; Radioimmunotherapy; Radiosensitization; Refractory; Regulatory T-Lymphocyte; Resistance; Role; Scientist; Solid Neoplasm; Speech; System; T memory cell; T-Lymphocyte; Testing; Travel; Treatment Efficacy; Tumor Immunity; antagonist; anti-PD-1; anti-PD1 therapy; anti-tumor immune response; antitumor effect; barrier to care; cancer recurrence; cancer therapy; cell type; checkpoint inhibition; chemoradiation; chemotherapy; cytotoxic CD8 T cells; design; efficacy testing; immune activation; immune checkpoint blockade; immune resistance; immunoregulation; inhibitor; malignant mouth neoplasm; malignant oropharynx neoplasm; mouse model; mouth squamous cell carcinoma; nanoparticle; nanoparticle delivery; neoplastic cell; novel; novel strategies; novel therapeutics; pre-clinical; programmed cell death protein 1; radiation effect; radiation resistance; radiation response; radioresistant; resistance gene; response; saliva secretion; side effect; small molecule; small molecule inhibitor; therapy resistant; tumor; tumor growth; tumor microenvironment; tumor-immune system interactions; uptake

PROJECT SUMMARY AND ABSTRACT: Radiation therapy (RT) is a mainstay of cancer treatment. However many tumors are resistant to RT, making it possible for microscopic tumor cells to remain or travel to other parts of the body and cause cancer recurrence at a later date. Immunotherapies can train the patient’s immune system to seek out and identify hidden tumor cells. The combination of RT with immunotherapy is a very exciting approach, but RT can have both immune- stimulating and immune suppressive effects, and further study is needed to understand how best to combine RT with immunotherapy. Many scientists now believe that understanding the tumor microenvironment – the types of cells which make up a tumor, and their interactions – is required to maximize the immune-stimulating effects of RT. We have discovered a strategy to alter the balance of cells in the tumor microenvironment of oral cancer and other solid tumor types, by simultaneously targeting immunosuppressive myeloid derived suppressor cells (MDSC) and regulatory T cells (Treg), so that immune-stimulating effects of RT predominate. Studies in mouse tumors show that this strategy is particularly effective when combined with an immunotherapy approach called “checkpoint inhibition” that targets molecules that limit effectiveness of anti- tumor T cells. This leads to our scientific hypothesis that tumor-infiltrating MDSC and Treg render the tumor microenvironment resistant to immune activation by RT and/or checkpoint inhibition, and limit the induction of tumor-specific CD8+ T cells and other immune effector immune cells. The goals of this proposal are to 1) determine whether modulating the tumor immune microenvironment enhances responsiveness of oral cancer to RT and/or checkpoint inhibition, leading to long-lasting and powerful anti-tumor effects; 2) determine the immunological mechanisms which make these combination therapies effective; and 3) develop a novel drug formulation which will make this approach more effective and suitable for testing in clinical trials. We will accomplish these goals by carrying out the following specific aims: In Aim 1 we will functionally dissect the immune mechanisms by which MDSC contribute to radioresistance in mouse oral cancer models. In Aim 2 we will assess the ability of dual targeting of MDSC and Treg to sensitize oral cancer to treatment with RT + anti-PD-1 and induce durable protective memory responses. In Aim 3 we will develop a novel drug delivery system that can enhance delivery of inhibitors of MDSC function directly to the tumor and tumor-infiltrating MDSC.

项目摘要和摘要： 放射治疗(RT)是癌症治疗的支柱。然而，许多肿瘤对RT具有耐药性，使其 微小的肿瘤细胞可能残留或转移到身体的其他部位并导致癌症复发 在以后的日子里。免疫疗法可以训练患者的免疫系统寻找和识别隐藏的肿瘤 细胞。RT与免疫治疗的结合是一种非常令人兴奋的方法，但RT可以同时具有免疫- 刺激和免疫抑制作用，还需要进一步的研究来了解如何最好地结合 RT加免疫治疗。许多科学家现在认为，了解肿瘤微环境-- 构成肿瘤的细胞类型及其相互作用是最大化免疫刺激所必需的 RT的影响。我们发现了一种改变口腔肿瘤微环境中细胞平衡的策略 癌症和其他实体肿瘤类型，通过同时靶向免疫抑制髓系来源的 抑制细胞(MDSC)和调节性T细胞(Treg)，使RT的免疫刺激作用占主导地位。 对小鼠肿瘤的研究表明，当与一种 一种名为“检查点抑制”的免疫治疗方法，其靶向是限制抗病毒效果的分子。 肿瘤T细胞。这导致了我们的科学假设，即肿瘤浸润性MDSC和Treg呈现肿瘤 通过RT和/或检查点抑制抵抗免疫激活的微环境，并限制诱导 肿瘤特异性CD8+T细胞和其他免疫效应免疫细胞。这项提案的目标是1) 确定调节肿瘤免疫微环境是否增强口腔癌的反应性 RT和/或检查点抑制，导致持久和强大的抗肿瘤作用；2)确定 使这些联合疗法有效的免疫学机制；以及3)开发一种新药 这将使这种方法更有效，更适合在临床试验中进行测试。我们会 通过实现以下具体目标来实现这些目标： 在目标1中，我们将从功能上剖析MDSC促进辐射抵抗的免疫机制。 在小鼠口腔癌模型中。 在目标2中，我们将评估MDSC和Treg双靶向增敏口腔癌治疗的能力。 RT+抗PD-1并诱导持久的保护性记忆反应。 在目标3中，我们将开发一种新的药物输送系统，该系统可以增强MDSC功能的抑制剂的输送 直接进入肿瘤和肿瘤浸润性MDSC。